PURPOSE: To illustrate changes in bleb vascularity after subconjunctival bevacizumab injection. METHODS: Longitudinal changes in bleb vascularity were followed over 6 months pre and postbevacizumab injection. RESULTS: Bleb vascularity associated with increased scarring activity was observed 10 days postcataract surgery in an eye that had undergone trabeculectomy 3 months previously. A single subconjunctival avastin injection led to a dramatic reduction in bleb vascularity for 6 weeks. With continued steroids, a diffuse, healthy, well functioning bleb with minimal scar tissue was present at 6 months. CONCLUSIONS: Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.
PURPOSE: To illustrate changes in bleb vascularity after subconjunctival bevacizumab injection. METHODS: Longitudinal changes in bleb vascularity were followed over 6 months pre and postbevacizumab injection. RESULTS: Bleb vascularity associated with increased scarring activity was observed 10 days postcataract surgery in an eye that had undergone trabeculectomy 3 months previously. A single subconjunctival avastin injection led to a dramatic reduction in bleb vascularity for 6 weeks. With continued steroids, a diffuse, healthy, well functioning bleb with minimal scar tissue was present at 6 months. CONCLUSIONS: Subconjunctival injection of bevacizumab reduced bleb vascularity and may provide an adjunct to current antifibrosis therapy. Further studies to establish the effect of bevacizumab on postoperative scaring are warranted.